Sign In
Buy AEMD
$1.36
-0.0200 (-1.45%)
At Close: Jun 23, 2026
Poster Presentation Reviews the Hemopurifier ® Affinity Resin's A bility to Bind Extracellular Vesicles in Long COVID Samples SAN DIEGO , June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: A
Results Reinforce the Current Australian Oncology Clinical Trial and Support Investigation of the Hemopurifier Across Multiple Indications SAN DIEGO , May 14, 2025 /PRNewswire/ -- Aethlon Medical, In
Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal
08:01am, Monday, 10'th Mar 2025
Preclinical Data Suggests Expanded Therapeutic Potential of the Hemopurifier® Beyond Virology and Oncology Results Support Further Evaluation of the Hemopurifier ® as Part of a Machine Perfusion C
Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025
08:01am, Thursday, 13'th Feb 2025
Aethlon Medical invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO , Feb. 1
Aethlon Medical, Inc. (AEMD) Q3 2025 Earnings Call Transcript
08:11pm, Wednesday, 12'th Feb 2025
Aethlon Medical, Inc. (NASDAQ:AEMD ) Q3 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Jim Frakes – Chief Executive Officer Steven LaRosa – Chief Medical Officer C
Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update
04:15pm, Wednesday, 12'th Feb 2025
Key Milestone Achieved: First Patient treated in Hemopurifier® Safety, Feasibility, and Dose Finding Study for Solid Tumors Not Responding to Anti-PD-1 Antibodies Patient Enrollment Open at Two Aust
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025
08:01am, Wednesday, 05'th Feb 2025
SAN DIEGO , Feb. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, to
Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial
08:01am, Wednesday, 29'th Jan 2025
First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN
Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu
08:01am, Friday, 20'th Dec 2024
SAN DIEGO , Dec. 20, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases,
Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally
08:00am, Thursday, 14'th Nov 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 14, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases a snapshot
Aethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call Transcript
07:58pm, Wednesday, 13'th Nov 2024
Aethlon Medical, Inc. (NASDAQ:AEMD ) Q2 2025Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations, Rx Communications James Frakes - Interim Chi
Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
04:15pm, Wednesday, 13'th Nov 2024
Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 An
Innovative Medical Technology Advances with First Patient Enrollments
08:00am, Tuesday, 12'th Nov 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 12, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical te
Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia
08:01am, Monday, 11'th Nov 2024
Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024
08:01am, Wednesday, 06'th Nov 2024
SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, to
